http://orcid.org/0000-0001-5975-1886
References
- Decramer M, Vogelmeier C. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2016. p. 20–30. Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016.
- Melani AS. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930–938.
- Lavorini F, Megnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102:593–604.
- Laube, BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialists should know about new inhalation therapies. Eur Respir J 2011;37:1308–1331.
- Kondo T, Hibino M, Ohe M, Akazawa K, Tanigaki T, Kato S. Feasibility of instruction of dry powder inhaler usage showing inhalation flow profile and drug dispersion (in Japanese). J Jpn Soc Respir Care Rehab 2015;25:222–224.
- Kim CS, Hu SC, DeWitt P, Gerrity TR. Assessment of regional deposition of inhaled particles in human lungs by serial bolus delivery method. J Appl Physiol 1996;81:2203–2213.
- Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111–1115.
- Demoly P, Hagedoorn P, Boer AH, Frijlink HW. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med 2014;108:1195–1203.